Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Abstract Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limited. Therefore, the present study evaluated ctDNA during osimertinib adm...

Full description

Bibliographic Details
Main Authors:	Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshitaka Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-11-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-48210-5

Similar Items

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
by: Kyoichi Kaira, et al.
Published: (2021-11-01)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib
by: Kyoichi Kaira, et al.
Published: (2023-10-01)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
by: Atsuto Mouri, et al.
Published: (2019-04-01)

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
by: Ou Yamaguchi, et al.
Published: (2020-04-01)

Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer
by: Kosuke Hashimoto, et al.
Published: (2024-11-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
by: Kyoichi Kaira, et al.
Published: (2023-01-01)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
by: Hisao Imai, et al.
Published: (2022-05-01)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
by: Atsuto Mouri, et al.
Published: (2021-03-01)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
by: Ou Yamaguchi, et al.
Published: (2021-02-01)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
by: Kyoichi Kaira, et al.
Published: (2020-10-01)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
by: Norimitsu Kasahara, et al.
Published: (2020-08-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
by: Ayako Shiono, et al.
Published: (2019-04-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients
by: Hiroshi Kagamu, et al.
Published: (2020-01-01)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
by: Ayako Shiono, et al.
Published: (2023-01-01)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
by: Ou Yamaguchi, et al.
Published: (2019-04-01)

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
by: Kyoichi Kaira, et al.
Published: (2023-03-01)

Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report
by: Ayako Shiono, et al.
Published: (2022-10-01)

Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
by: Ou Yamaguchi, et al.
Published: (2022-07-01)

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
by: Hisao Imai, et al.
Published: (2021-10-01)

Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
by: Kyoichi Kaira, et al.
Published: (2021-01-01)

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature
by: Shiono Ayako, et al.
Published: (2024-09-01)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
by: Satoshi Wasamoto, et al.
Published: (2023-01-01)

Prognostic significance of LAT1 expression in pleural mesothelioma
by: Ryo Taguchi, et al.
Published: (2024-09-01)

Primary resistance to osimertinib despite acquired T790M
by: Ling‐Kai Chang, et al.
Published: (2020-03-01)

Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor
by: Hisao Imai, et al.
Published: (2021-09-01)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
by: Hiroshi Soda, et al.
Published: (2019-02-01)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
by: Kei Morikawa, et al.
Published: (2020-10-01)

Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy
by: Hiroshi Shintani, et al.
Published: (2021-12-01)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
by: Xiaoying Zhang
Published: (2021-06-01)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
by: Asim Joshi, et al.
Published: (2022-08-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1
by: Ou Yamaguchi, et al.
Published: (2022-12-01)

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study
by: Hisao Imai, et al.
Published: (2021-12-01)

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2
by: Chidiebere U. Awah, et al.
Published: (2024-04-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)